A multi-institutional team of researchers at the University of Toronto has unveiled a next-generation RNA therapeutic platform designed to target the root genetic causes of thousands of currently untreatable diseases. Published in the journal Science on August 27, the landmark study centers on the engineering of transfer RNA (tRNA) to bypass premature stop signals within cellular genetic code. By bridging the gap between fundamental molecular biology and advanced drug delivery systems, this innovation offers a unified therapeutic strategy for genetic disorders that share common underlying mutations, including specific subsets of cystic fibrosis, muscular dystrophy, and various oncology indications.
The urgency for broad-spectrum genetic medicines has intensified as modern diagnostics identify increasingly granular subtypes of rare and inherited disorders. Historically, gene therapy and targeted drug development have focused on individual mutations or specific genes. However, with thousands of distinct disease-causing variants affecting small patient populations, developing bespoke therapies for every individual genetic signature remains economically and logistically prohibitive. The University of Toronto team’s approach seeks to circumvent this barrier by focusing on shared mutational mechanics rather than individual disease manifestations.
Mechanics of Nonsense Mutations and the tRNA Solution
At the heart of the newly developed platform is the biological phenomenon of nonsense mutations. These genetic alterations introduce a premature stop codon into the messenger RNA (mRNA) instructions that cells use to synthesize proteins. Normally, ribosomes read mRNA sequentially until they encounter a stop signal, which indicates that protein assembly is complete. When a nonsense mutation occurs prematurely, the ribosome halts production early, resulting in a truncated, non-functional protein—or no protein at all.
Although nonsense mutations account for an estimated 11 percent of all inherited genetic disorders, their sheer diversity means they impact millions of patients globally across thousands of distinct conditions. Diseases driven by these errors span multiple organ systems, including the lungs, brain, and muscular tissues.
To combat this, the research team engineered transfer RNA molecules—the cellular components responsible for delivering specific amino acids to ribosomes during protein synthesis. By chemically modifying these tRNAs, the scientists enabled them to ignore or "read through" the premature stop signals, allowing the cellular machinery to complete the production of full-length, functional proteins.
Dr. Bowen Li, an associate professor in the University of Toronto’s Leslie Dan Faculty of Pharmacy and an affiliate scientist at the University Health Network’s Princess Margaret Cancer Centre, served as the study’s lead investigator.
"There are so many types of disease-causing mutations—many affecting only a small number of people—that developing a separate gene therapy for every individual mutation is extremely challenging," Dr. Li explained. "With tRNA therapeutics, our goal is to develop a common therapeutic approach that could potentially address the same type of mutation across many different genes and diseases, including rare conditions that currently have few or no effective treatment options."
Interdisciplinary Synergy: Chemistry Meets RNA Biology
Developing an engineered tRNA capable of operating efficiently within human cells required bridging distinct scientific disciplines. Study co-lead Dr. Haissi Cui, an assistant professor of chemistry in the University of Toronto’s Faculty of Arts & Science, guided the team toward a biomimetic strategy inspired by natural tRNA structures.
Rather than relying entirely on synthetic modifications, the researchers analyzed natural tRNAs to identify chemical tags that enhance stability and performance. By incorporating one specific chemical modification discovered through this analysis, the team successfully engineered a tRNA variant that demonstrated significantly higher activity and prolonged persistence inside cells.
"Interdisciplinary collaboration was key to this project," Dr. Cui noted. "We used nature as our design guide and found that adding one specific modification made the engineered tRNA more active and longer-lasting. It shows what becomes possible when chemistry and RNA biology come together."
However, overcoming intracellular hurdles was only half the battle. A molecular payload, regardless of its potency, is therapeutically useless if it cannot safely reach the targeted cells within a living organism. Jingan (Charles) Chen, a PhD candidate in the Leslie Dan Faculty of Pharmacy and the Institute of Biomedical Engineering, tackled the critical challenge of delivery.
The research team adapted lipid nanoparticles (LNPs)—the microscopic fatty bubbles famously utilized to encapsulate and transport fragile mRNA in COVID-19 vaccines. Because tRNA possesses distinct biochemical properties compared to mRNA, standard LNP formulations were ineffective. The team engineered a specialized, cargo-specific lipid nanoparticle delivery system optimized explicitly for tRNA transport.
"No matter how powerful you make those tRNAs, without delivery, they cannot be a drug," Chen stated. "That cargo-specific delivery system is one of the major advances of our study. We used a tailored lipid nanoparticle delivery system that is specifically developed for tRNA."
Preclinical Validation and Combination Therapy in Cystic Fibrosis
To validate the platform’s clinical potential, the researchers focused heavily on cystic fibrosis, a genetic condition traditionally caused by mutations in the CFTR gene. In recent years, the management of cystic fibrosis has been revolutionized by CFTR modulator drugs, such as Trikafta, which repair and activate misshapen chloride channel proteins.
However, approximately 10 percent of cystic fibrosis patients harbor nonsense mutations. Because these patients fail to produce the CFTR protein entirely, modulators like Trikafta—which require an existing protein structure to modify—are completely ineffective.
Testing the engineered tRNA in human airway cells bearing two common nonsense mutations, the research team observed not only the restoration of full-length CFTR protein production, but also the successful restoration of its biological function. Crucially, the newly synthesized proteins remained stable and functional within the cells for more than 40 days.
To push the model closer to clinical reality, the researchers collaborated with Dr. Jim Hu and Dr. Tanja Gonska, scientists at SickKids and faculty members in the University of Toronto’s Temerty Faculty of Medicine. These investigators provided biological tissue samples from a cystic fibrosis patient carrying a complex genotype featuring four distinct mutations—including two nonsense mutations—rendering the patient entirely unresponsive to standard modulator therapies.
The patient cells were cultivated in the laboratory into miniature organoids. When treated with the engineered tRNA alone or Trikafta alone, the cells exhibited minimal response. However, when the tRNA and Trikafta were administered in combination, a synergistic effect occurred. The engineered tRNA successfully induced the production of the full-length CFTR protein, thereby supplying the structural foundation necessary for Trikafta to activate the ion channel. This finding suggests a viable pathway for treating patient populations previously deemed untreatable by existing pharmaceutical regimens.
Institutional Legacy and Future Horizons
The milestone discovery aligns with the University of Toronto’s historic legacy of translating fundamental biological research into globally impactful medical treatments. Dr. Lisa Dolovich, dean of the Leslie Dan Faculty of Pharmacy, contextualized the study within the institution’s rich history of biomedical breakthroughs, which includes the discovery of insulin and the foundational peptide research that ultimately enabled modern metabolic therapies such as Ozempic.
"This is the kind of foundational research that medical breakthroughs are built on," Dr. Dolovich said. "By tackling the science and the delivery together, we’re closer to turning a discovery into a drug."
With the foundational science established, Dr. Li’s laboratory is actively planning the next phase of development. Future research will focus on expanding the tRNA platform to target genetic diseases affecting other vital organ systems. Because different organs present unique physiological barriers, each application will require a specialized delivery architecture.
For pulmonary conditions like cystic fibrosis, the team has already demonstrated that their lipid nanoparticle formulations can withstand mechanical nebulization—transforming the liquid therapeutic into a fine mist. This crucial engineering milestone establishes the preliminary framework for a non-invasive, home-administered inhalation therapy, bringing advanced genetic medicine one step closer to everyday clinical practice.
